Background: Cost-of-Illness Analysis (COI) constitutes the basis for the decision-making process on the budget and allocation in a modern health care system. Considering the wide prevalence of type 2 diabetes mellitus (Т2DM), it is important to perform COI in the Russian Federation (RF). Aim: The aim of the secondary objective FORSIGHT-Т2DM study was to conduct Cost-of-Illness Analysis (COI) of Т2DM in the Russian Federation in relation to taking into consideration the presence of complications and concomitant diseases. Materials and methods: COI of Т2DM was performed using the data obtained in Russian multicenter observational, pharmacoepidemiologic cross-sectional study of diabetes care for assessing routine healthcare pattern of T2DM in the Russian Federation (FORSIGHT-Т2DM). Information for each patient was collected from primary medical records and By asking patients to fill out a questionnaire. Total costs were calculated as the sum of direct medical costs (DCm), direct non-medical costs (DCn) and indirect costs (IC). Results: The final analysis included data from 2014 patients with T2DM residing in 45 cities of RF. Total direct medical costs (DCm) of treating Т2DM and its complications and comorbidities amounted to 105 337 rubles ($2742) per patient per year; direct non-medical costs (DCn) amounted to 24 518 rubles ($638) per patient per year; indirect costs (IC) amounted to 149 754 rubles ($3898) per patient per year. The total cost of T2DM in RF in 2014 year amounted to 279 609 rubles ($7278) per patient. The total cost of T2DM in RF in 2014 amounted to 279 609 rubles per patient. Conclusions: More than half (53,5%) of the total cost of T2DM is the loss of GDP due to patients disability. The DCm constitute 37,7% of the total cost of the disease, of which 57% is spent on treatment of T2DM complications and concomitant diseases, while only 10% is spent on glucose-lowering therapies.
16 March 2023 in Medical Technologies. Assessment and Choice
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить использование ресурсов здравоохранения и социально-экономическое бремя заболевания у пациентов с впервые выявленной легочной артериальной гипертензией (ЛАГ) до верификации диагноза и в течение первых 12 мес лечения, а также влияние назначенной терапии на эти показатели в условиях реальной клинической практики. МАТЕРИАЛ И МЕТОДЫ Выполнено ретроспективно-проспективное наблюдательное исследование, в которое включены пациенты с различными формами ЛАГ после верификации диагноза с помощью катетеризации правых отделов сердца (КПОС). Необходимые данные собраны путем интервьюирования пациентов и анализа медицинской документации в момент включения в исследование и каждые 3 мес после него. Ряд пациентов (57,6%) включены в исследование через несколько месяцев после проведения КПОС, но не более чем через 12 мес. В рамках исследования оценивались прямые и непрямые затраты. Общий период наблюдения каждого пациента составил 1 год до верификации диагноза и 1 год после нее. РЕЗУЛЬТАТЫ В исследование включены 33 пациента. Медиана общих затрат на ЛАГ на 1 пациента в год составила 234 570,07 руб. до и 1 501 175,08 руб. после верификации диагноза: медиана прямых затрат — 110 661/902 456 руб., медиана прямых немедицинских затрат — 2 213/74 025 руб., медиана непрямых затрат — 80 477/52 972 руб. до и после верификации ЛАГ соответственно. Таким образом, после верификации диагноза ЛАГ происходило статистически значимое увеличение затрат на ЛАГ (p=0,11·10–4), что связано с затратами на ЛАГ-специфическую терапию. Вместе с тем после установления диагноза ЛАГ отмечалось статистически значимое снижение всех прямых затрат, за исключением затрат на ЛАГ-специфическую терапию, и снижение затрат на госпитализацию (p=0,2·10–5). Статистически значимого изменения прямых немедицинских (p=0,53) и непрямых затрат после верификации диагноза не было (p=0,31). ЗАКЛЮЧЕНИЕ Ранняя диагностика и лучший доступ к ЛАГ-специфической терапии повысят качество медицинской помощи больным ЛАГ и повлекут за собой разумные государственные расходы на лечение этих больных. Несмотря на увеличение затрат на ЛАГ-специфическую терапию, ранняя ее инициация может улучшить качество жизни пациентов и избежать дополнительных затрат на госпитализацию.
Background/Objectives: In recent decades, the number of patients with chronic cardiovascular diseases (CVDs) has increased, and CVD survivors are more likely to be old and frail and to have multiple comorbidities. A better understanding of geriatric conditions and their prevalence would help improve the management of older patients with CVDs. The main objective of this study is to estimate the association of myocardial infarction (MI) history with geriatric syndromes (GSs) in people 65 years of age and older. Methods: The cross-sectional study EVKALIPT included patients who were 65 years of age and older. All patients underwent a comprehensive geriatric assessment. The presence of MI history was assessed by medical records. Results: A total of 4295 participants were included. The prevalence of MI history was 12.6%. According to univariate regression analysis, MI history was associated with an increase in the odds of 12 GSs by 1.3–2.4 times. Multivariate regression analysis showed that male sex and four GSs (impairment in basic and instrumental activities of daily living, depression, falls) were independently associated with a history of MI, with the odds ratio ranging from 1.28 to 1.86. Conclusions: This study showed the association between MI history and GSs.
30 April 2024 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Objective. The aim of the study is to examine treatment patterns, hospitalizations, work disability and describe demographic and clinical characteristics of newly diagnosed patients with pulmonary arterial hypertension (PAH) before and after diagnosis verification in real clinical practice in Russia. Design and methods. Longitudinal prospective observational study with a retrospective part was conducted. Adult patients were included after PAH verification based on right heart catheterization. The data was received via patients interviewing and medical documentation analysis at enrollment and every 3 months. The retrospective design was used to collect information before enrollment. Results. Thirty-three patients with newly diagnosed PAH were enrolled in the study. Most patients had II (45,5 %) or III (36,4 %) WHO functional class. During follow-up period 2 patients died because of PAH complications, 1 patient died due to COVID-19 complications, and 1 patient was lost for follow-up. Before PAH verification 12,1 % of all patients did not work due to PAH symptoms while after verification of the diagnosis this proportion doubled. Diuretics and mineralocorticoid-receptor antagonists were the most frequently used drugs before PAH diagnosis confirmation, 9 % of patients took sildenafil. Most patients (64 %) received monotherapy as initial PAH-specific treatment, in 34 % of all patients treatment was escalated within 12 months after PAH verification. The number of hospitalizations significantly decreased after PAH verification and specific therapy prescription (р < 0,05). Conclusions. This study demonstrated a decrease in the number of hospitalizations after PAH verification, which may confirm the effectiveness of various regimens of PAH-specific therapy in real clinical practice in Russia. In addition, the study identified a number of problems associated with PAH (predominance of initial monotherapy, low vaccination coverage, problems with drug provision, etc.) The solution of these problems may improve the outcomes.
To the Editor A recent article reported a positive effect of a traditional Chinese drug (Tongxinluo) on outcomes of patients with acute myocardial infarction. T
The activity of the renin-angiotensin-aldosterone system is one of the main pathogenetic mechanisms underlying cardiovascular diseases at all stages of the cardiovascular continuum. This article discusses the role of telmisartan and azilsartan as the most powerful sartans in modern cardiology. Azilsartan and especially telmisartan have a significant organoprotection and are superior to other antihypertensive drugs in terms of lowering blood pressure. However, the effect of azilsartan on hard endpoints has not been studied while the efficacy of telmisartan on hard endpoints has been evaluated in plenty clinical trials including 3 large randomized clinical trials with several thousand patients. The article also presents calculations showing the better cost-effectiveness of telmisartan compared to azilsartan.